Yuki Nakamura_No.3
- kawaokashinpei3
- 3 days ago
- 2 min read
Selected journal : Cell
Macrophage-mediated myelin recycling fuels brain cancer malignancy
What is the main question of the paper?
How do macrophages within glioblastomas promote tumor malignancy and recurrence?
How did the anthor address the question?
■Step1
1. Identification of lipid-laden macrophages (LLMs)
Using a genetically modified glioblastoma mouse model, as well as primary tumors and tumors that recurred after radiation therapy, they combined single-cell RNA sequencing (scRNA-seq) with spatial transcriptomics to demonstrate that LLMs—lipid-accumulated, immunosuppressive macrophages—are increased in highly malignant MES-like glioblastomas.
■Step2
2. Elucidation of how LLMs form
They confirmed that macrophages within the tumor phagocytose myelin debris. Furthermore, they demonstrated that myelin uptake causes macrophages to accumulate cholesterol, leading to their transformation into immunosuppressive LLMs—a process accompanied by activation of the LXR pathway, suppression of inflammation-related genes, increased PD-L1 expression, and reduced MHC class II expression.
■Step3
3. Demonstrating that LLMs transfer myelin-derived lipids to tumor cells and promote malignancy
They demonstrated that MES-like glioblastoma exhibits low lipid and cholesterol synthesis activity and is dependent on exogenous lipids. Although tumor cells cannot directly utilize myelin, in the presence of macrophages, myelin debris is phagocytosed, and cholesterol and lipids are transferred to MES-like tumor cells. Tracing experiments demonstrated that macrophage-derived lipids are directly transferred to MES-like tumor cells. As a result, they determined that the proliferation of MES-like tumor cells is promoted, leading to increased tumor cell survival. Furthermore, when lipid transfer was blocked by CD36 inhibition, LXR inhibition, ABCA1 inhibition, or macrophage-specific Abca1/Abcg1 deficiency, the tumor-promoting effect of LLMs was lost. In a mouse model, the combination of a CD36 inhibitor and radiation therapy prolonged survival. Patient data also showed that patients with a high LLM signature were more likely to have the MES subtype, had a poor prognosis, and were associated with poor response to immune checkpoint inhibitors.
What is the “strength” of the paper?
The strength of this study lies in the discovery of a novel tumor-promoting mechanism in which macrophages convert the brain’s native myelin into a nutrient source for tumor cells. The study has identified several potential therapeutic targets, suggesting the possibility of clinical applications.
Comment
I found the dual protective mechanism of macrophages particularly compelling. Unprocessed myelin debris exerts lipotoxicity that inhibits tumor cells; macrophages serve as an essential metabolic mediator by scavenging this debris to clear the toxicity, before safely transferring the recycled lipids to fuel cancer cell progression.
Comment by Xiaoran Ma
